EBAMed ist ein in Genf ansässiges Medizintechnikunternehmen im aufstrebenden und zukunftsgerichteten Bereich der Protonentherapie. Das Unternehmen entwickelt ein neuartiges Behandlungsverfahren, um die Herzbewegungen während einer kardialen Radioablation zu überwachen und darauf zu reagieren. Ziel ist es, das Volumen des gesunden Herzens, das während einer kardialen Radioablation mehr als 20 Gray Protonen/Photonen ausgesetzt ist, zu reduzieren und damit die langfristige Sicherheit für die Patienten zu maximieren.
Location: Switzerland, Geneva
Employees: 1-10
Total raised: $18.62M
Founded date: 2018
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.01.2025 | Series A | $1.68M | - |
| 27.06.2023 | Series A | $15.72M | - |
| 22.08.2019 | Seed | $1.22M | - |
Mentions in press and media 28
| Date | Title | Description |
| 27.01.2025 | EBAMed secures EUR 1.6M, concluding Series A Round at EUR 16M | EBAMed has secured additional funding from CDP Venture Capital under the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. This marks the startup's achievement of the EUR 16 million maximum investment out... |
| 24.01.2025 | EBAMed completes Series A with EUR 1.6M investment | The new funds were raised from CDP Venture Capital as part of the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. This significant new milestone brings the startup led by CEO Marina Izzo to the maximum... |
| 28.06.2023 | EUR 14.35 million to advance cardiac radiation ablation therapy | |
| 27.06.2023 | EBAMed raises EUR 14.35 million in Series A Funding for non-invasive ventricular tachycardia treatment | EBAMed raises EUR 14.35 million in Series A Funding for non-invasive ventricular tachycardia treatment 27.06.2023 14:20, Rita Longobardi linkedIn facebook twitter instagram youtube --> The funding will be used to develop further their in... |
| 27.06.2023 | EBAMed raises EUR 14.35 million in series A funding for non-invasive ventricular tachycardia treatment | EBAMed raises EUR 14.35 million in series A funding for non-invasive ventricular tachycardia treatment 27.06.2023 14:20, Rita Longobardi linkedIn facebook twitter instagram youtube --> The funding will be used to develop further their in... |
| 27.06.2023 | EBAMed raises EUR 14.35 million in Series A Funding for non-invasive ventricular tachycardia treatment | EBAMed SA, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias, announced today the raising of 14.35 M € in Series A Funding to accelerate the development of an innovative devic... |
| 22.09.2022 | FIF funding supports three women led deeptech startups | The FIF is the instrument for fostering innovation and the scale up of promising companies from the Canton of Geneva at the service of the United Nations (UN) Sustainable Development Goals (SDGs). The FIF is supported by the State of Geneva... |
| 27.07.2021 | First Patient enrolled in EBAMed Prospective Imaging Study | The first patient was enrolled at the Policlinico San Matteo, Pavia (Italy). This important company milestone was reached according to development schedule. The main objectives of the study are to collect cardiac ultrasound data from patien... |
| 26.02.2021 | Female leaders at the top | |
| 26.02.2021 | Female leaders at the top | EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as CEO. Izzo served as CEO for Cardionovum, an innovative developer of drug-coated balloon tech... |
Show more